- Home
- PAXS vs UPB Comparison
PAXS vs UPB Comparison
Compare PAXS & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- UPB
- Stock Information
- Founded
- PAXS 2021
- UPB 2021
- Country
- PAXS United States
- UPB United States
- Employees
- PAXS N/A
- UPB N/A
- Industry
- PAXS Investment Managers
- UPB
- Sector
- PAXS Finance
- UPB
- Exchange
- PAXS Nasdaq
- UPB NYSE
- Market Cap
- PAXS 722.0M
- UPB 622.8M
- IPO Year
- PAXS N/A
- UPB 2024
- Fundamental
- Price
- PAXS $15.58
- UPB $11.00
- Analyst Decision
- PAXS
- UPB Strong Buy
- Analyst Count
- PAXS 0
- UPB 4
- Target Price
- PAXS N/A
- UPB $56.50
- AVG Volume (30 Days)
- PAXS 195.0K
- UPB 442.0K
- Earning Date
- PAXS 01-01-0001
- UPB 02-14-2025
- Dividend Yield
- PAXS 11.72%
- UPB N/A
- EPS Growth
- PAXS N/A
- UPB N/A
- EPS
- PAXS N/A
- UPB N/A
- Revenue
- PAXS N/A
- UPB $2,207,000.00
- Revenue This Year
- PAXS N/A
- UPB N/A
- Revenue Next Year
- PAXS N/A
- UPB N/A
- P/E Ratio
- PAXS N/A
- UPB N/A
- Revenue Growth
- PAXS N/A
- UPB 82.10
- 52 Week Low
- PAXS $12.57
- UPB $10.36
- 52 Week High
- PAXS $15.93
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- PAXS 46.66
- UPB N/A
- Support Level
- PAXS $15.29
- UPB N/A
- Resistance Level
- PAXS $15.93
- UPB N/A
- Average True Range (ATR)
- PAXS 0.25
- UPB 0.00
- MACD
- PAXS 0.02
- UPB 0.00
- Stochastic Oscillator
- PAXS 59.77
- UPB 0.00
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.